Pipeline
We are building a robust pipeline of transformative medicines addressing inflammatory and autoimmune diseases, and fibrosis.
Using our Deep Biology platform, we are advancing multiple large molecule therapeutic candidates with the potential to be first-in-class therapeutics. Our most advanced product candidates are outlined in the chart below:
Immunology
Program
Therapeutic Area
Indications
Discovery
Lead Optimization
IND Enabling
Clinical
Product Rights
TRB-061
TNFR2
Derm, GI
Atopic Derm, IBD
IND Enabling
TRB-071
Immunology
IND Enabling
TRB-081
Immunology
Lead Optimization
TRB-051
Immunology
Clinical
TRB-041
Immunology
Lead Optimization
Immunology
Oncology
*Partnered with Eli Lilly.
Discovery Pipeline
In addition to these therapeutic programs, we are developing a broad research pipeline by applying our Deep Biology Platform, identifying novel insights into tissue immune-regulation to drive target identification.
Our Collaborations
We have established a number of collaborations and partnerships with leading industry and academic institutions. Notably, we work with Eli Lilly across 3 programs that have been identified and characterized leveraging TRex’s Deep Biology platform : TRB-031, TRB-041, and TRB-051. We also entered into a collaboration with Johnson & Johnson Innovative Medicine for novel targets in Immunology & Inflammation.
